JIAS Symposium: Advancing Use of Long-Acting HIV Treatment and Prevention Regimens

To highlight some of the key findings from the JIAS supplement on Advancing use of long‐acting and extended delivery (LAED) HIV prevention and treatment regimens, JIAS held a symposium titled “Advancing Use of Long-Acting HIV Treatment and Prevention Regimens” on February 2, 2024. It offered a comprehensive overview of the ongoing research on long-acting regimens access, delivery, and choice, included community perspectives, discussed future directions, and concluded with a panel discussion. 

3 February 2024
Chairs
Kenneth H. Mayer

Kenneth H. Mayer

Professor of Medicine, Director and Co-chair

Harvard Medical School and the Medical Research and Fenway Institute

Annette Sohn

Annette Sohn

Vice President and Director

TREAT Asia amfAR

Charles Flexner

Charles Flexner

Professor of Medicine

Johns Hopkins University School of Medicine

Sinéad Delany-Moretlwe

Sinéad Delany-Moretlwe

Research professor and research director

Wits RHI at the University of the Witwatersrand, Johannesburg

Speakers

Gesine Meyer-Rath

University of the Witwatersrand and Boston University

Facilitating access to long-acting regimens. Supply- and demand-side considerations
Kenneth Ngure

Kenneth Ngure

Associate Professor

Jomo Kenyatta University of Agriculture and Technology

Delivery of Long-Acting Extended Delivery (LAED) Regimens
Ariane van der Straten

Ariane van der Straten

Adjunct Professor

University of California San Francisco (UCSF)

Choice of long-acting and extended delivery regimens for prevention
Peter Kim

Peter Kim

Director

Therapeutics Research Program at the Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Dianne Rausch

Division of AIDS Research, National Institute of Mental Health, National Institutes of Health

Ensuring Impact of Long-acting HIV Therapeutics through Multi-level Treatment Research: Future Research Directions
Beatriz Grinsztejn

Beatriz Grinsztejn

Head

STD/AIDS Clinical Research Laboratory Fundação Oswaldo Cruz (Fiocruz)

Panel discussion and Q/A